Anwendungsgebiet
Treatment of osteoporosis: in post-menopausal women; in men; at increased risk of fracture, including those with a recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture. Treatment of Paget's disease of the bone.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.
- AclastaBrasilien · Sandoz do Brasil Indústria Farmacêutica LtdaGleiche Marke
- AclastaBrasilien · Novartis Biociencias S.AGleiche Marke
- AclastaKanada · 5 MG / 100 ML · Solution · Sandoz Canada IncorporatedGleiche Marke
- ACLASTA 5 mg SOLUCION PARA PERFUSIONSpanien · 5 mg · solución para perfusión · Sandoz Pharmaceuticals D.D.